이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Panbela Therapeutics 미래 성장

Future 기준 확인 0/6

Panbela Therapeutics 의 수익은 연간 4.3% 감소할 것으로 예상되는 반면, 연간 수익은 82.4% 로 증가할 것으로 예상됩니다. 82.4% 연간. EPS는 연간 53% 만큼 성장할 것으로 예상됩니다.

주요 정보

-4.3%

수익 성장률

53.0%

EPS 성장률

Biotechs 수익 성장	30.3%
매출 성장률	82.4%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	11 Apr 2023

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:X70 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	N/A	-52	N/A	N/A	2
12/31/2024	N/A	-32	N/A	N/A	2
12/31/2023	N/A	-22	N/A	N/A	2
12/31/2022	N/A	-35	-16	-15	N/A
9/30/2022	N/A	-34	-13	-12	N/A
6/30/2022	N/A	-31	-12	-12	N/A
3/31/2022	N/A	-12	-9	-9	N/A
12/31/2021	N/A	-10	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-4	-4	N/A
9/30/2020	N/A	-5	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-6	-3	-3	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-6	-2	-2	N/A
6/30/2019	N/A	-6	-2	-2	N/A
3/31/2019	N/A	-6	-3	-3	N/A
12/31/2018	N/A	-6	-2	-2	N/A
9/30/2018	N/A	-7	-3	-3	N/A
6/30/2018	N/A	-8	-3	-3	N/A
3/31/2018	N/A	-7	-3	-3	N/A
12/31/2017	N/A	-10	-3	-3	N/A
9/30/2017	N/A	-10	-3	-3	N/A
6/30/2017	N/A	-10	-4	-4	N/A
3/31/2017	N/A	-10	-3	-3	N/A
12/31/2016	N/A	-5	-2	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

애널리스트 미래 성장 예측

수입 대 저축률: X70 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: X70 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: X70 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: X70 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: X70 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: X70 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Panbela Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Therapeutics, Inc. Announces Nasdaq Files A Form 25 Notification of Removal from Listing

Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025

Panbela Announces Poster Presentation At American Association for Cancer Research

Panbela Therapeutics, Inc. has filed a Follow-on Equity Offering.

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(4)

Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma

Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes

Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication

Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.510816 million.

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Therapeutics Regains Compliance with Nasdaq Listing Standards

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.01875 million.

Panbela Therapeutics, Inc. Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Panbela Therapeutics, Inc. Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Panbela Therapeutics Receives a Notification Letter from Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics Receives a Letter from The Nasdaq Stock Market LLC Regarding Minimum Stockholders' Equity Requirement

Panbela Therapeutics, Inc. Receives Approval from Australian Human Research Ethics Committee to Expand Global Clinical Trial to Australia

Panbela Therapeutics, Inc. Announces the Publication of Preclinical Data from Studies of SBP-101

Less than half of directors are independent

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견